Rajendrakumar H. Jani

Mersacidin, a new antibiotic from Bacillus In vitro and in vivo antibacterial activity.

Sukumar Chatterjee, DIPAK KUMAR CHATTERJEE, Rajendrakumar H. Jani et al. · The Journal of Antibiotics · 1992 · 144 citations · Full text

A Multicenter, Prospective, Randomized, Double-Blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared with Placebo in Type 2 Diabetes Mellitus Patients Having Hypertriglyceridemia Not Controlled with Atorvastatin Therapy (PRESS VI)

Rajendrakumar H. Jani, Vikas Pai, Pramod Jha et al. · Diabetes Technology & Therapeutics · 2013 · 110 citations · Full text

A Multicenter, Prospective, Randomized, Double-blind Study to Evaluate the Safety and Efficacy of Saroglitazar 2 and 4 mg Compared to Pioglitazone 45 mg in Diabetic Dyslipidemia (PRESS V)

Vikas Pai, A Paneerselvam, Satinath Mukhopadhyay et al. · Journal of Diabetes Science and Technology · 2014 · 108 citations · Full text

A prospective, randomized, double‐blind, multicentre, parallel‐group, active controlled study to compare efficacy and safety of biosimilar adalimumab (Exemptia;<scp>ZRC</scp>‐3197) and adalimumab (Humira) in patients with rheumatoid arthritis

Rajendrakumar H. Jani, Rajiv Gupta, Girish Bhatia et al. · International Journal of Rheumatic Diseases · 2015 · 62 citations · Full text

Pharmacokinetics, Safety, and Tolerability of Saroglitazar (ZYH1), a Predominantly PPARα Agonist with Moderate PPARγ Agonist Activity in Healthy Human Subjects

Rajendrakumar H. Jani, Kevinkumar Kansagra, Mukul R. Jain et al. · Clinical Drug Investigation · 2013 · 58 citations · Full text